Conduit Pharmaceuticals Inc. (CDT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) has a cash flow conversion efficiency ratio of 0.031x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($42.74 Million) by net assets ($1.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Conduit Pharmaceuticals Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Conduit Pharmaceuticals Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Conduit Pharmaceuticals Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Conduit Pharmaceuticals Inc. ranked by their cash flow conversion efficiency. Explore Conduit Pharmaceuticals Inc. cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Curis Inc
NASDAQ:CRIS
|
-0.708x |
|
Abrdn UK Smaller Companies Growth Trust PLC
LSE:AUSC
|
0.008x |
|
Hansa Trust
LSE:HAN
|
0.324x |
|
Vistal Gdynia
WAR:VTL
|
0.003x |
|
Transition Evergreen
PA:EGR
|
0.008x |
|
FAT Brands Inc
NASDAQ:FAT
|
0.024x |
|
Riwi Corp
V:RIWI
|
-0.140x |
|
Concurrent Technologies Plc
LSE:CNC
|
-0.053x |
Annual Cash Flow Conversion Efficiency for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Conduit Pharmaceuticals Inc. from 2021 to 2025. View Conduit Pharmaceuticals Inc. (CDT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.26 Billion | $-15.55 Million | -0.012x | -100.86% |
| 2024-12-31 | $-6.79 Million | $-9.68 Million | 1.425x | -91.57% |
| 2023-12-31 | $-457.00K | $-7.72 Million | 16.904x | +7426.11% |
| 2022-12-31 | $-10.09 Million | $-2.27 Million | 0.225x | +100.22% |
| 2021-12-31 | $20.62K | $-2.15 Million | -104.321x | -- |
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more